1. Induced Disease Models Products Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor
  2. Cardiovascular System Disease Models Urinary System Disease Models Mineralocorticoid Receptor Endogenous Metabolite
  3. Hypertension Models
  4. Deoxycorticosterone acetate

Deoxycorticosterone acetate  (Synonyms: 11-Deoxycorticosterone acetate; DOC acetate; Cortexone acetate)

Cat. No.: HY-B1472 Purity: 99.57%
COA Handling Instructions

Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria.

For research use only. We do not sell to patients.

Deoxycorticosterone acetate Chemical Structure

Deoxycorticosterone acetate Chemical Structure

CAS No. : 56-47-3

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
100 mg USD 60 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Deoxycorticosterone acetate:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria[1][2].

IC50 & Target

Human Endogenous Metabolite

 

In Vivo

Deoxycorticosterone acetate (2.5 mg/day; s.c. implantation) with Tamoxifen (HY-13757A) (42 d; 2 mg/day) pre-treatment) induces hypertension by increasing blood pressure and cardiac hypertrophy in mice[1].

1. Induction of Hypertension[3][4]
Background
Deoxycorticosterone acetate (DOCA) inhibits the renin-angiotensin system, resulting in low plasma renin activity, thereby mediating an increase in blood pressure
Specific Mmodeling Methods
Rat: Sprague-Dawley with a right nephrectomy • male • 250 to 300 g
Administration: 100 mg slow-release DOCA pellet was inserted subcutaneously and drinking water is replaced by 1% saline; 21 days
Rat: Sprague-Dawley with a right nephrectomy • male • 160 to 180 g
Administration: 15 mg/kg • sc • and drinking water is replaced by 1% saline; twice weekly for 2 weeks
Modeling Indicators
Pathological changes: systolic blood pressure increase, superoxide (vascular O2??) increase
Correlated Product(s):
Opposite Product(s):Atrasentan (HY-15403) A-192621 (HY-120295)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MR (mineralocorticoid receptor) mutant mice (MRCdh5Cre) and MR wild-type mice (MRwild-type) treated with unilateral nephrectomy (12-week-old)[1]
Dosage: 2.5 mg/d
Administration: Subcutaneous implantation; 42 days; treated with 2 mg Tamoxifen (HY-13757A) (20 mg/mL in sunflower oil and 10% ethanol; i.p.; once daily on 5 consecutive days) at least 4 weeks before nephrectomy
Result: Increased the blood pressure without differences between both genotypes (MRCdh5Cre and MRwild-type).
Resulted glomerular injury and proteinuria, renal inflammation and fibrosis.
Molecular Weight

372.50

Formula

C23H32O4

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]12[C@@H](C(COC(C)=O)=O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC2)=O

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
Solvent & Solubility
In Vitro: 

DMSO : 16.67 mg/mL (44.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.6846 mL 13.4228 mL 26.8456 mL
5 mM 0.5369 mL 2.6846 mL 5.3691 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (5.58 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.08 mg/mL (5.58 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.57%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.6846 mL 13.4228 mL 26.8456 mL 67.1141 mL
5 mM 0.5369 mL 2.6846 mL 5.3691 mL 13.4228 mL
10 mM 0.2685 mL 1.3423 mL 2.6846 mL 6.7114 mL
15 mM 0.1790 mL 0.8949 mL 1.7897 mL 4.4743 mL
20 mM 0.1342 mL 0.6711 mL 1.3423 mL 3.3557 mL
25 mM 0.1074 mL 0.5369 mL 1.0738 mL 2.6846 mL
30 mM 0.0895 mL 0.4474 mL 0.8949 mL 2.2371 mL
40 mM 0.0671 mL 0.3356 mL 0.6711 mL 1.6779 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Deoxycorticosterone acetate
Cat. No.:
HY-B1472
Quantity:
MCE Japan Authorized Agent: